plexiform神経線維腫治療の世界市場

plexiform神経線維腫治療の世界市場は2030年までに18億米ドルに達する

2024年に12億米ドルと推定されるplexiform神経線維腫治療の世界市場は、2024～2030年の分析期間においてCAGR 6.5%で成長し、2030年には18億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるセルメチニブは、CAGR 5.0％を記録し、分析期間終了時には6億3,240万米ドルに達すると予測されます。非ステロイド性抗炎症薬セグメントの成長率は、分析期間中CAGR 8.1%と推定されます。

米国市場は推定3億3,500万米ドル、中国はCAGR 10.0％で成長予測

米国のplexiform神経線維腫治療市場は2024年に3億3,500万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGR10.0％を追いかけ、2030年には予測市場規模3億6,520万米ドルに達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ3.3％と6.3％と予測されています。欧州では、ドイツがCAGR 4.3%で成長すると予測されています。

世界のplexiform神経線維腫治療市場- 主要動向と促進要因のまとめ

plexiform神経線維腫治療が希少腫瘍管理および遺伝性疾患ケアで急増している理由とは？

叢状神経線維腫（PN）は、良性ではあるが、しばしば衰弱させる腫瘍であり、NF1遺伝子の変異によって引き起こされる遺伝性疾患である1型神経線維腫症（NF1）に関連します。これらの腫瘍は末梢神経に沿って発生し、周辺組織に浸潤することがあり、疼痛、醜形、運動制限、および気道閉塞や悪性化などの生命を脅かす合併症を引き起こす可能性があります。PNの治療は歴史的に外科的切除に限られてきたが、腫瘍がびまん性で浸潤性であるため、高い再発率と神経損傷のリスクを伴う。

標的治療薬、特にセルメチニブなどのMEK阻害薬の導入は、PN管理のパラダイムシフトをもたらしました。症候性で手術不能のPNを有する小児患者を対象にFDAから承認されたセルメチニブは、NF1変異の下流にあるMAPK経路を阻害し、腫瘍体積の縮小と症状の改善をもたらします。これは、PNを縮小させる有効性が実証された初めての薬物治療であり、これまで手術や支持療法のみに頼っていた患者に新たな希望を与えるものです。NF1に対する臨床的理解が深まるにつれて、神経腫瘍学と遺伝医学の広い分野の中で、PNに対する治療開発が加速しています。

NF1関連腫瘍の治療選択肢を広げる薬剤開発と遺伝子標的治療とは？

臨床パイプラインは、新しいMEK阻害剤（トラメチニブ、ビニメチニブなど）、mTOR阻害剤、および有効性を改善し耐性メカニズムに対処するように設計された併用レジメンで拡大しています。成人PN患者におけるこれらの薬剤の安全性と有効性を評価するための試験が進行中であり、免疫療法や放射線治療との併用も検討されています。現在進行中のバイオマーカー研究は、反応者を同定し、最小限の毒性で最大限の腫瘍制御が得られるように投与量を最適化することを目的としています。

これと並行して、NF1遺伝子やその下流のエフェクターを標的とした遺伝子編集療法やアンチセンスオリゴヌクレオチド（ASO）療法が前臨床段階に入りつつあります。これらのアプローチは、単に増殖シグナル伝達を阻害するのではなく、その根底にある遺伝的機能障害を修正しようとするものです。さらに、患者由来の異種移植片やオルガノイドモデルは、PNの挙動をシミュレートし、個別化医療の枠組みで新規化合物を評価するために使用されています。容積測定MRIのような先進的な画像診断法もまた、経時的な腫瘍負荷と反応を正確に測定することを可能にし、治療モニタリングを強化しています。

世界的に治療需要とイノベーションを牽引している患者集団と研究機関は？

小児NF1患者は最大の初期治療コホートであり、特に、機能を損ない、痛みを引き起こし、解剖学的構造を歪める、症状のある手術不能なPNを持つ患者です。進行性のPNを有する成人や、悪性末梢神経鞘腫瘍（MPNST）転化のリスクが高い成人は、治療介入の二次的対象集団として浮上しています。神経線維腫症の集学的センター、小児腫瘍病院、臨床研究機関が、患者の募集、治療試験、データ収集を主導しています。

北米、特に米国は、NIH、Children's Tumor Foundation、主要大学病院などの機関に支えられ、NF1研究と医薬品承認活動の中心地であり続けています。欧州も活発で、ドイツ、フランス、英国の研究拠点が、欧州希少神経疾患調査ネットワーク（European Reference Network for Rare Neurological Diseases）のようなコンソーシアムを通じて共同試験を行っています。アジア太平洋では、認知度と診断率の向上が需要を支えており、観察研究や初期段階の試験への関与が増加しています。遺伝子スクリーニングが日常的に行われるようになるにつれ、PN患者の特定と管理は世界的に大幅に拡大すると予想されます。

plexiform神経線維腫治療市場の長期的成長と戦略的前進の原動力は？

plexiform神経線維腫治療市場の成長の原動力は、遺伝子研究の進歩、希少疾病治療薬の政策的インセンティブ、希少疾病治療に対するアドボカシーの高まりです。規制当局が画期的な治療法に対して迅速な経路を提供する中、製薬会社はアンメットニーズを満たす高精度医薬品に投資しています。希少医薬品の指定、市場独占権、小児優先審査バウチャーは、技術革新を促進し、効果的なPN療法の市場投入までの時間を短縮しています。

戦略的には、バイオファーマ企業は、治療法の開発と商業化のために、学術センター、患者支援団体、ゲノムデータプラットフォームとパートナーシップを結んでいます。コンパニオン診断薬、バイオマーカー主導型臨床試験、および実臨床エビデンス登録は、疾患の進行と治療効果に関する理解を深めています。NF1に対する認識が臨床および患者コミュニティの双方で高まるにつれ、早期診断と介入が優先事項となり、有意義な腫瘍制御、QOLの改善、および長期寛解の可能性を提供する新規治療に対する需要が高まっています。この新たな治療フロンティアにおいて、PNは医学的課題であるだけでなく、複雑な遺伝性疾患の治療における革新への入り口でもあります。

セグメント

薬剤クラス（セルメチニブ、非ステロイド性抗炎症薬、抗けいれん薬、その他の薬剤クラス）;人口動態（小児、成人）;販売チャネル（病院薬局、小売薬局、オンライン薬局）

調査対象企業の例（全39件）

• AbbVie Inc.
• Alexion Pharmaceuticals, Inc.
• Amgen Inc.
• AstraZeneca plc
• Bayer AG
• BioMarin Pharmaceutical Inc.
• Bristol Myers Squibb
• CureAge Therapeutics
• Eli Lilly and Company
• Genentech, Inc.
• GlaxoSmithKline plc
• Johnson & Johnson
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• Regeneron Pharmaceuticals
• Roche Holding AG
• Sanofi S.A.
• SpringWorks Therapeutics, Inc.
• Takeda Pharmaceutical Company

関税影響係数

Global Industry Analystsは、本社国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

お客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・産業団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストの厳選されたグループを含む1万4,949人のエコノミストを追跡しています。当社の16,491を超えるレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Plexiform Neurofibromas Treatment Market to Reach US$1.8 Billion by 2030

The global market for Plexiform Neurofibromas Treatment estimated at US$1.2 Billion in the year 2024, is expected to reach US$1.8 Billion by 2030, growing at a CAGR of 6.5% over the analysis period 2024-2030. Selumetinib, one of the segments analyzed in the report, is expected to record a 5.0% CAGR and reach US$632.4 Million by the end of the analysis period. Growth in the Non-Steroidal Anti-Inflammatory Drugs segment is estimated at 8.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$335.0 Million While China is Forecast to Grow at 10.0% CAGR

The Plexiform Neurofibromas Treatment market in the U.S. is estimated at US$335.0 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$365.2 Million by the year 2030 trailing a CAGR of 10.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.3% and 6.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.3% CAGR.

Global Plexiform Neurofibromas Treatment Market - Key Trends & Drivers Summarized

Why Is Plexiform Neurofibromas Treatment Gaining Urgency in Rare Tumor Management and Genetic Disorder Care?

Plexiform neurofibromas (PNs) are benign but often debilitating tumors associated with Neurofibromatosis Type 1 (NF1), a genetic disorder caused by mutations in the NF1 gene. These tumors can develop along peripheral nerves and infiltrate surrounding tissues, leading to pain, disfigurement, mobility limitations, and potentially life-threatening complications such as airway obstruction or malignant transformation. Treatment for PNs has historically been limited to surgical excision, which carries high recurrence rates and risks of nerve damage due to the tumor’s diffuse and invasive nature.

The introduction of targeted therapies-most notably MEK inhibitors such as selumetinib-has marked a paradigm shift in PN management. Approved by the FDA for pediatric patients with symptomatic, inoperable PNs, selumetinib inhibits the MAPK pathway downstream of the NF1 mutation, leading to tumor volume reduction and symptomatic improvement. This is the first pharmacologic treatment with demonstrated efficacy in shrinking PNs, offering new hope for patients previously reliant solely on surgery or supportive care. As clinical understanding of NF1 deepens, therapeutic development for PNs is accelerating within the broader field of neuro-oncology and genetic medicine.

How Are Drug Development and Gene-Targeted Therapies Expanding Treatment Options for NF1-Related Tumors?

Clinical pipelines are expanding with new MEK inhibitors (e.g., trametinib, binimetinib), mTOR inhibitors, and combination regimens designed to improve efficacy and address resistance mechanisms. Trials are underway to assess their safety and effectiveness in adult PN patients, as well as in combination with immunotherapies or radiologic interventions. Ongoing biomarker studies aim to identify responders and optimize dosage for maximal tumor control with minimal toxicity.

In parallel, gene-editing and antisense oligonucleotide (ASO) therapies targeting the NF1 gene or its downstream effectors are entering preclinical development. These approaches seek to correct the underlying genetic dysfunction rather than merely inhibit proliferative signaling. Additionally, patient-derived xenografts and organoid models are being used to simulate PN behavior and evaluate new compounds in a personalized medicine framework. Advanced imaging modalities like volumetric MRI are also enhancing treatment monitoring by enabling precise measurement of tumor burden and response over time.

Which Patient Populations and Research Institutions Are Driving Therapeutic Demand and Innovation Globally?

Pediatric NF1 patients represent the largest initial treatment cohort, especially those with symptomatic, inoperable PNs that compromise function, cause pain, or distort anatomy. Adults with progressive PNs or those with a high risk of malignant peripheral nerve sheath tumor (MPNST) transformation are emerging as a secondary target population for therapeutic intervention. Multidisciplinary centers for neurofibromatosis, pediatric oncology hospitals, and clinical research organizations are leading patient recruitment, treatment trials, and data collection.

North America-especially the U.S.-remains the epicenter of NF1 research and drug approval activity, supported by institutions such as the NIH, Children’s Tumor Foundation, and leading university hospitals. Europe is also active, with research hubs in Germany, France, and the UK conducting collaborative trials through consortia like the European Reference Network for Rare Neurological Diseases. Asia-Pacific is increasingly involved in observational studies and early-phase trials, with growing awareness and diagnosis rates supporting demand. As genetic screening becomes more routine, global identification and management of PN patients is expected to expand significantly.

What Is Driving Long-Term Growth and Strategic Advancement in the Plexiform Neurofibromas Treatment Market?

The growth in the plexiform neurofibromas treatment market is driven by advances in genetic research, orphan drug policy incentives, and increased advocacy for rare disease therapies. As regulators offer expedited pathways for breakthrough treatments, pharmaceutical companies are investing in precision drugs that meet unmet clinical needs in NF1. Orphan drug designations, market exclusivity, and pediatric priority review vouchers are fueling innovation and reducing time-to-market for effective PN therapies.

Strategically, biopharma firms are forming partnerships with academic centers, patient advocacy organizations, and genomic data platforms to develop and commercialize therapies. Companion diagnostics, biomarker-driven trials, and real-world evidence registries are enhancing understanding of disease progression and treatment response. As awareness of NF1 grows within both the clinical and patient communities, early diagnosis and intervention are becoming priorities-fueling demand for novel therapies that offer meaningful tumor control, improved quality of life, and potential long-term remission. In this emerging therapeutic frontier, PNs represent not only a medical challenge but a gateway to innovation in treating complex genetic disorders.

SCOPE OF STUDY:

The report analyzes the Plexiform Neurofibromas Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Class (Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants, Other Drug Classes); Demographic (Pediatric, Adult); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 39 Featured) -

• AbbVie Inc.
• Alexion Pharmaceuticals, Inc.
• Amgen Inc.
• AstraZeneca plc
• Bayer AG
• BioMarin Pharmaceutical Inc.
• Bristol Myers Squibb
• CureAge Therapeutics
• Eli Lilly and Company
• Genentech, Inc.
• GlaxoSmithKline plc
• Johnson & Johnson
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• Regeneron Pharmaceuticals
• Roche Holding AG
• Sanofi S.A.
• SpringWorks Therapeutics, Inc.
• Takeda Pharmaceutical Company

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Impact of Covid-19 and a Looming Global Recession
  • Plexiform Neurofibromas Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Advances in Genetic Research and Precision Medicine Propel Development of Targeted Therapies
  • Increasing Approval of Pediatric Drugs Strengthens Treatment Options for Plexiform Neurofibromas
  • Rising Healthcare Expenditure and Infrastructure Development Expand Access to Specialized Treatments
  • Growing Awareness and Improved Diagnostic Techniques Enhance Early Detection Rates
  • Strong Product Pipeline and Clinical Trials Accelerate Introduction of Novel Therapeutics
  • Outsourcing of Drug Development Activities Spurs Innovation in Treatment Modalities
  • Expansion of Orphan Drug Designations Encourages Investment in Rare Disease Therapies
  • Personalized Medicine Approaches Enhance Efficacy and Patient Outcomes
  • Integration of Multidisciplinary Care Models Improves Management of Complex Cases
  • Government Initiatives and Funding Support Research and Development Efforts
  • Collaboration Between Academic Institutions and Biopharmaceutical Companies Drives Innovation
  • Technological Advancements in Imaging and Surgical Techniques Improve Treatment Precision
  • Patient Advocacy and Support Groups Increase Awareness and Funding Opportunities
  • Regulatory Incentives and Fast-Track Approvals Facilitate Market Entry of New Treatments
  • Challenges in Treatment Accessibility and Affordability Highlight Need for Policy Reforms
  • Emergence of Gene Therapy and CRISPR Technologies Opens New Avenues for Treatment
  • Expansion of Telemedicine Services Enhances Patient Monitoring and Follow-Up Care
  • Development of Biomarkers Aids in Treatment Personalization and Monitoring
  • Increasing Prevalence of Neurofibromatosis Type 1 Drives Demand for Effective Therapies
  • Strategic Partnerships and Mergers Among Key Players Strengthen Market Position
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Plexiform Neurofibromas Treatment Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Plexiform Neurofibromas Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Plexiform Neurofibromas Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Selumetinib by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Selumetinib by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Selumetinib by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Non-Steroidal Anti-Inflammatory Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Non-Steroidal Anti-Inflammatory Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Non-Steroidal Anti-Inflammatory Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Anticonvulsants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Anticonvulsants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Anticonvulsants by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Pediatric by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Pediatric by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Pediatric by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Adult by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Adult by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Adult by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Plexiform Neurofibromas Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 32: USA Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 33: USA Historic Review for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 34: USA 15-Year Perspective for Plexiform Neurofibromas Treatment by Drug Class - Percentage Breakdown of Value Sales for Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 35: USA Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 36: USA Historic Review for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 37: USA 15-Year Perspective for Plexiform Neurofibromas Treatment by Demographic - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
  • TABLE 38: USA Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 39: USA Historic Review for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 40: USA 15-Year Perspective for Plexiform Neurofibromas Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 41: Canada Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 42: Canada Historic Review for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 43: Canada 15-Year Perspective for Plexiform Neurofibromas Treatment by Drug Class - Percentage Breakdown of Value Sales for Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 44: Canada Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 45: Canada Historic Review for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 46: Canada 15-Year Perspective for Plexiform Neurofibromas Treatment by Demographic - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
  • TABLE 47: Canada Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Canada Historic Review for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 49: Canada 15-Year Perspective for Plexiform Neurofibromas Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• JAPAN
  • Plexiform Neurofibromas Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 50: Japan Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Japan Historic Review for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 52: Japan 15-Year Perspective for Plexiform Neurofibromas Treatment by Drug Class - Percentage Breakdown of Value Sales for Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 53: Japan Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Japan Historic Review for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 55: Japan 15-Year Perspective for Plexiform Neurofibromas Treatment by Demographic - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
  • TABLE 56: Japan Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Japan Historic Review for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 58: Japan 15-Year Perspective for Plexiform Neurofibromas Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• CHINA
  • Plexiform Neurofibromas Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 59: China Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 60: China Historic Review for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 61: China 15-Year Perspective for Plexiform Neurofibromas Treatment by Drug Class - Percentage Breakdown of Value Sales for Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 62: China Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 63: China Historic Review for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 64: China 15-Year Perspective for Plexiform Neurofibromas Treatment by Demographic - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
  • TABLE 65: China Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 66: China Historic Review for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 67: China 15-Year Perspective for Plexiform Neurofibromas Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• EUROPE
  • Plexiform Neurofibromas Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 68: Europe Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 69: Europe Historic Review for Plexiform Neurofibromas Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 70: Europe 15-Year Perspective for Plexiform Neurofibromas Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 71: Europe Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Europe Historic Review for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 73: Europe 15-Year Perspective for Plexiform Neurofibromas Treatment by Drug Class - Percentage Breakdown of Value Sales for Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 74: Europe Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Europe Historic Review for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 76: Europe 15-Year Perspective for Plexiform Neurofibromas Treatment by Demographic - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
  • TABLE 77: Europe Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Europe Historic Review for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 79: Europe 15-Year Perspective for Plexiform Neurofibromas Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• FRANCE
  • Plexiform Neurofibromas Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 80: France Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 81: France Historic Review for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 82: France 15-Year Perspective for Plexiform Neurofibromas Treatment by Drug Class - Percentage Breakdown of Value Sales for Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 83: France Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 84: France Historic Review for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 85: France 15-Year Perspective for Plexiform Neurofibromas Treatment by Demographic - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
  • TABLE 86: France Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 87: France Historic Review for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 88: France 15-Year Perspective for Plexiform Neurofibromas Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• GERMANY
  • Plexiform Neurofibromas Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 89: Germany Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Germany Historic Review for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 91: Germany 15-Year Perspective for Plexiform Neurofibromas Treatment by Drug Class - Percentage Breakdown of Value Sales for Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 92: Germany Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Germany Historic Review for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 94: Germany 15-Year Perspective for Plexiform Neurofibromas Treatment by Demographic - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
  • TABLE 95: Germany Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Germany Historic Review for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 97: Germany 15-Year Perspective for Plexiform Neurofibromas Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 98: Italy Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Italy Historic Review for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 100: Italy 15-Year Perspective for Plexiform Neurofibromas Treatment by Drug Class - Percentage Breakdown of Value Sales for Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 101: Italy Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Italy Historic Review for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 103: Italy 15-Year Perspective for Plexiform Neurofibromas Treatment by Demographic - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
  • TABLE 104: Italy Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Italy Historic Review for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 106: Italy 15-Year Perspective for Plexiform Neurofibromas Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Plexiform Neurofibromas Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 107: UK Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 108: UK Historic Review for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 109: UK 15-Year Perspective for Plexiform Neurofibromas Treatment by Drug Class - Percentage Breakdown of Value Sales for Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 110: UK Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 111: UK Historic Review for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 112: UK 15-Year Perspective for Plexiform Neurofibromas Treatment by Demographic - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
  • TABLE 113: UK Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 114: UK Historic Review for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 115: UK 15-Year Perspective for Plexiform Neurofibromas Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 116: Spain Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Spain Historic Review for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 118: Spain 15-Year Perspective for Plexiform Neurofibromas Treatment by Drug Class - Percentage Breakdown of Value Sales for Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 119: Spain Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Spain Historic Review for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 121: Spain 15-Year Perspective for Plexiform Neurofibromas Treatment by Demographic - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
  • TABLE 122: Spain Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Spain Historic Review for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 124: Spain 15-Year Perspective for Plexiform Neurofibromas Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 125: Russia Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Russia Historic Review for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 127: Russia 15-Year Perspective for Plexiform Neurofibromas Treatment by Drug Class - Percentage Breakdown of Value Sales for Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 128: Russia Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Russia Historic Review for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 130: Russia 15-Year Perspective for Plexiform Neurofibromas Treatment by Demographic - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
  • TABLE 131: Russia Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Russia Historic Review for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 133: Russia 15-Year Perspective for Plexiform Neurofibromas Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Rest of Europe Historic Review for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 136: Rest of Europe 15-Year Perspective for Plexiform Neurofibromas Treatment by Drug Class - Percentage Breakdown of Value Sales for Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Rest of Europe Historic Review for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 139: Rest of Europe 15-Year Perspective for Plexiform Neurofibromas Treatment by Demographic - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
  • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Rest of Europe Historic Review for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 142: Rest of Europe 15-Year Perspective for Plexiform Neurofibromas Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Plexiform Neurofibromas Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 144: Asia-Pacific Historic Review for Plexiform Neurofibromas Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 145: Asia-Pacific 15-Year Perspective for Plexiform Neurofibromas Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Asia-Pacific Historic Review for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 148: Asia-Pacific 15-Year Perspective for Plexiform Neurofibromas Treatment by Drug Class - Percentage Breakdown of Value Sales for Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Asia-Pacific Historic Review for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 151: Asia-Pacific 15-Year Perspective for Plexiform Neurofibromas Treatment by Demographic - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
  • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Asia-Pacific Historic Review for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 154: Asia-Pacific 15-Year Perspective for Plexiform Neurofibromas Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Plexiform Neurofibromas Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 155: Australia Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Australia Historic Review for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 157: Australia 15-Year Perspective for Plexiform Neurofibromas Treatment by Drug Class - Percentage Breakdown of Value Sales for Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 158: Australia Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Australia Historic Review for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 160: Australia 15-Year Perspective for Plexiform Neurofibromas Treatment by Demographic - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
  • TABLE 161: Australia Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Australia Historic Review for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 163: Australia 15-Year Perspective for Plexiform Neurofibromas Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• INDIA
  • Plexiform Neurofibromas Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 164: India Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 165: India Historic Review for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 166: India 15-Year Perspective for Plexiform Neurofibromas Treatment by Drug Class - Percentage Breakdown of Value Sales for Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 167: India Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 168: India Historic Review for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 169: India 15-Year Perspective for Plexiform Neurofibromas Treatment by Demographic - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
  • TABLE 170: India Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 171: India Historic Review for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 172: India 15-Year Perspective for Plexiform Neurofibromas Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 173: South Korea Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 174: South Korea Historic Review for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 175: South Korea 15-Year Perspective for Plexiform Neurofibromas Treatment by Drug Class - Percentage Breakdown of Value Sales for Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 176: South Korea Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 177: South Korea Historic Review for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 178: South Korea 15-Year Perspective for Plexiform Neurofibromas Treatment by Demographic - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
  • TABLE 179: South Korea Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 180: South Korea Historic Review for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 181: South Korea 15-Year Perspective for Plexiform Neurofibromas Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Rest of Asia-Pacific Historic Review for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 184: Rest of Asia-Pacific 15-Year Perspective for Plexiform Neurofibromas Treatment by Drug Class - Percentage Breakdown of Value Sales for Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Rest of Asia-Pacific Historic Review for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 187: Rest of Asia-Pacific 15-Year Perspective for Plexiform Neurofibromas Treatment by Demographic - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
  • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Rest of Asia-Pacific Historic Review for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 190: Rest of Asia-Pacific 15-Year Perspective for Plexiform Neurofibromas Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Plexiform Neurofibromas Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 191: Latin America Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 192: Latin America Historic Review for Plexiform Neurofibromas Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 193: Latin America 15-Year Perspective for Plexiform Neurofibromas Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 194: Latin America Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Latin America Historic Review for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 196: Latin America 15-Year Perspective for Plexiform Neurofibromas Treatment by Drug Class - Percentage Breakdown of Value Sales for Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 197: Latin America Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Latin America Historic Review for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 199: Latin America 15-Year Perspective for Plexiform Neurofibromas Treatment by Demographic - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
  • TABLE 200: Latin America Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Latin America Historic Review for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 202: Latin America 15-Year Perspective for Plexiform Neurofibromas Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 203: Argentina Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Argentina Historic Review for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 205: Argentina 15-Year Perspective for Plexiform Neurofibromas Treatment by Drug Class - Percentage Breakdown of Value Sales for Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 206: Argentina Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Argentina Historic Review for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 208: Argentina 15-Year Perspective for Plexiform Neurofibromas Treatment by Demographic - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
  • TABLE 209: Argentina Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Argentina Historic Review for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 211: Argentina 15-Year Perspective for Plexiform Neurofibromas Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 212: Brazil Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Brazil Historic Review for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 214: Brazil 15-Year Perspective for Plexiform Neurofibromas Treatment by Drug Class - Percentage Breakdown of Value Sales for Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 215: Brazil Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Brazil Historic Review for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 217: Brazil 15-Year Perspective for Plexiform Neurofibromas Treatment by Demographic - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
  • TABLE 218: Brazil Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Brazil Historic Review for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 220: Brazil 15-Year Perspective for Plexiform Neurofibromas Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 221: Mexico Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Mexico Historic Review for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 223: Mexico 15-Year Perspective for Plexiform Neurofibromas Treatment by Drug Class - Percentage Breakdown of Value Sales for Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 224: Mexico Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Mexico Historic Review for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 226: Mexico 15-Year Perspective for Plexiform Neurofibromas Treatment by Demographic - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
  • TABLE 227: Mexico Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Mexico Historic Review for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 229: Mexico 15-Year Perspective for Plexiform Neurofibromas Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Rest of Latin America Historic Review for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 232: Rest of Latin America 15-Year Perspective for Plexiform Neurofibromas Treatment by Drug Class - Percentage Breakdown of Value Sales for Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Rest of Latin America Historic Review for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 235: Rest of Latin America 15-Year Perspective for Plexiform Neurofibromas Treatment by Demographic - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
  • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Rest of Latin America Historic Review for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 238: Rest of Latin America 15-Year Perspective for Plexiform Neurofibromas Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Plexiform Neurofibromas Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 239: Middle East Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 240: Middle East Historic Review for Plexiform Neurofibromas Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 241: Middle East 15-Year Perspective for Plexiform Neurofibromas Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 242: Middle East Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Middle East Historic Review for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 244: Middle East 15-Year Perspective for Plexiform Neurofibromas Treatment by Drug Class - Percentage Breakdown of Value Sales for Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 245: Middle East Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Middle East Historic Review for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 247: Middle East 15-Year Perspective for Plexiform Neurofibromas Treatment by Demographic - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
  • TABLE 248: Middle East Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Middle East Historic Review for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 250: Middle East 15-Year Perspective for Plexiform Neurofibromas Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 251: Iran Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Iran Historic Review for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 253: Iran 15-Year Perspective for Plexiform Neurofibromas Treatment by Drug Class - Percentage Breakdown of Value Sales for Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 254: Iran Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Iran Historic Review for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 256: Iran 15-Year Perspective for Plexiform Neurofibromas Treatment by Demographic - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
  • TABLE 257: Iran Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Iran Historic Review for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 259: Iran 15-Year Perspective for Plexiform Neurofibromas Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 260: Israel Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Israel Historic Review for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 262: Israel 15-Year Perspective for Plexiform Neurofibromas Treatment by Drug Class - Percentage Breakdown of Value Sales for Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 263: Israel Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Israel Historic Review for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 265: Israel 15-Year Perspective for Plexiform Neurofibromas Treatment by Demographic - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
  • TABLE 266: Israel Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Israel Historic Review for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 268: Israel 15-Year Perspective for Plexiform Neurofibromas Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Saudi Arabia Historic Review for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 271: Saudi Arabia 15-Year Perspective for Plexiform Neurofibromas Treatment by Drug Class - Percentage Breakdown of Value Sales for Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Saudi Arabia Historic Review for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 274: Saudi Arabia 15-Year Perspective for Plexiform Neurofibromas Treatment by Demographic - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
  • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Saudi Arabia Historic Review for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 277: Saudi Arabia 15-Year Perspective for Plexiform Neurofibromas Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 278: UAE Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 279: UAE Historic Review for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 280: UAE 15-Year Perspective for Plexiform Neurofibromas Treatment by Drug Class - Percentage Breakdown of Value Sales for Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 281: UAE Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 282: UAE Historic Review for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 283: UAE 15-Year Perspective for Plexiform Neurofibromas Treatment by Demographic - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
  • TABLE 284: UAE Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 285: UAE Historic Review for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 286: UAE 15-Year Perspective for Plexiform Neurofibromas Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Rest of Middle East Historic Review for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 289: Rest of Middle East 15-Year Perspective for Plexiform Neurofibromas Treatment by Drug Class - Percentage Breakdown of Value Sales for Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Rest of Middle East Historic Review for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 292: Rest of Middle East 15-Year Perspective for Plexiform Neurofibromas Treatment by Demographic - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
  • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Rest of Middle East Historic Review for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 295: Rest of Middle East 15-Year Perspective for Plexiform Neurofibromas Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• AFRICA
  • Plexiform Neurofibromas Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 296: Africa Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Africa Historic Review for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 298: Africa 15-Year Perspective for Plexiform Neurofibromas Treatment by Drug Class - Percentage Breakdown of Value Sales for Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 299: Africa Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Africa Historic Review for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 301: Africa 15-Year Perspective for Plexiform Neurofibromas Treatment by Demographic - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
  • TABLE 302: Africa Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Africa Historic Review for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 304: Africa 15-Year Perspective for Plexiform Neurofibromas Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030

IV. COMPETITION